pharma · Systemic Lupus Erythematosus · Lupus Erythematosus, Systemic
Serana Europe
Serono Europe Limited
Serono Europe is a pharma organization headquartered in GB. Primary therapeutic focus areas include Systemic Lupus Erythematosus, Lupus Erythematosus, Systemic, First Line Non-Small Cell Lung Cancer, Coronavirus Disease
Pessin, DE HQ
2014 Founded
20 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Pessin, DE
- Founded
- 2014
- Employees
- 20
- Programs
- 8
- Drugs
- 8
- Patents
- 0
Xevinapant (Debio 1143)
Phase 3 · small molecule · Squamous Cell Carcinoma of the Head and Neck
Xevinapant (Debio 1143) for Squamous Cell Carcinoma of the Head and Neck is a Phase 3 program (small_molecule) at Serono Europe Limited with 1 ClinicalTrials.gov record(s).
Internal code MS202359_0006
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Serono Europe Limited
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Squamous Cell Carcinoma of the Head and Neck
- Status
- terminated
- Trials
- 1